Pharmaceutical organizations face an unprecedented challenge - how to take advantage of new genomic data made available by efforts such as the Human Genome Project. While this information holds tremendous potential for new drug development, it has also resulted in a much-heightened risk of attrition for new drug candidates. This risk is predicted to inflate the costs of developing new drugs by two-fold in the next few years.
To minimize attrition rates and maximize the chances of being first to market with new drugs, some life sciences companies are using new research applications based on eXtensible Markup Language (XML). With XML, applications are better able to store, access and manage vast amounts of data.
Ipedo seamlessly integrates numerous sources of genomic data from drug databases, relates that data to information in journals, and provides scientists and analytic applications with the ability to search and analyze the data using sophisticated queries. The Ipedo solution also allows annotations to be made to add knowledge, and for the information to be shared with other researchers and steps in the drug discovery pipeline.